MAPT and Alzheimer disease: This is especially the case for pro-IAPPβ, with an AUROC of 0.89, which is in the range of accuracy for the most advanced immune assays for markers considered central to AD pathogenesis, such as Aβ (0.78) [64], soluble Aβ oligomers (0.89) [65], pTau217 (0.98), pTau181 (0.97) [66], N-terminal Tau fragment (0.95) [67], total Tau (0.78), and neurofilament light (0.87) [68] or even neuronal-derived extracellular vesicles (0.89) [69], which have been proposed as predictors of future AD diagnosis [70].